Analyst Price Target is $39.00
▲ +557.67% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Chemomab Therapeutics in the last 3 months. The average price target is $39.00, with a high forecast of $45.00 and a low forecast of $30.00. The average price target represents a 557.67% upside from the last price of $5.93.
Current Consensus is
The current consensus among 3 polled investment analysts is to buy stock in Chemomab Therapeutics.